GALECTIN THERAPEUTICS INC — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Richard E. Uihlein, Galectin's Chairman and largest shareholder, converted $105.8 million in outstanding debt (principal $91.0M + accrued interest $14.8M) into 34,376,167 shares of common stock on July 31, 2026, at a blended average conversion price of $3.07/share. This eliminates all debt under five line-of-credit facilities (a sixth $10M undrawn facility remains available). Post-conversion, 100,849,644 shares are outstanding.
Why this rating
Debt elimination equals 97% of current market cap; dramatically improves balance sheet solvency. Concentration risk and dilution offset gains. Meaningful for clinical-stage biotech survival.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.